window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Clinical Trials

  • Clinical Trials,Funding,Opthalmology,Pharmaceuticals and therapeutics,Research & Development

    Life Biosciences raises $80M to advance gene therapy for optic neuropathies

    Life Biosciences has raised $80m in a Series D financing [...]

    April 9, 2026
  • Clinical Trials,Pharmaceuticals and therapeutics,Research & Development

    Levicept reports Phase 2 osteoarthritis data in The Lancet showing pain reduction with LEVI-04

    Levicept has reported Phase 2 clinical trial results for LEVI-04 [...]

    March 30, 2026
  • Clinical Trials,Healthcare leadership,Women in Pharma

    Strong scientists: PHARMExcel’s Margaret Irwin on clinical research careers and early stage trials

    From hospital haematology to leading early stage clinical trials, Margaret [...]

    March 10, 2026
  • Biotech,Clinical Trials,FDA,Hematology,Rare Diseases,Regulatory Affairs

    Hemab Therapeutics wins FDA breakthrough therapy status for sutacimig in Glanzmann thrombasthenia

      The FDA has granted breakthrough therapy designation to Hemab [...]

    March 5, 2026
  • Chronic diseases,Clinical Development,Clinical studies,Drug Development,Drug discovery,Gastroenterology,Immunology,Pharmaceuticals and therapeutics

    Patients with Crohn’s disease maintain steroid-free remission for three years with Lilly’s Omvoh (mirikizumab)

    Long-term VIVID-2 data show more than 90% of patients with [...]

    February 19, 2026
  • Biologics & Biosimilars,Biomanufacturing,Biotech,Clinical Development,Clinical Trials,Drug approval,Drug Development,FDA,Rare Diseases,Research & Development

    Hansa Biopharma’s BLA for imlifidase accepted by FDA

    Hansa Biopharma’s Biologics License Application (BLA) for imlifidase has been [...]

    February 19, 2026
  • Artificial Intelligence,Clinical Development,Clinical Trials,Technology and platforms

    Evinova and Bristol Myers Squibb collaborate on AI-driven clinical trial optimisation

    Evinova and Bristol Myers Squibb have entered a strategic collaboration [...]

    February 9, 2026
  • Diagnostics,Hematology,Oncology,Real world evidence

    Quest Diagnostics launches flow cytometry MRD blood test for myeloma to support ultrasensitive monitoring

    Quest Diagnostics has introduced a new blood-based test for measurable [...]

    February 4, 2026
  • Clinical Trials,Digital Health,Patient Centricity,Real world evidence,Technology and platforms

    Kayentis and Ametris partner on integrated eCOA and wearable adherence platform

    Kayentis and Ametris have announced a strategic partnership to integrate [...]

    January 30, 2026
  • Clinical Trials,Data Management,Digital Health,Technology and platforms

    Zeroport raises $10 million seed to address remote access security risks in pharma and clinical trials

    Zeroport has raised $10 million in seed funding to expand [...]

    January 20, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: CDMOs & Manufacturing, Drug Development, European biotech, Logistics and distribution, Oncology, Partnerships & Funding, Supply Chain & Logistics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top